Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer

Ribas, R., Pancholi, S., Rani, A., Schuster, E., Guest, S., Nikitorowicz-Buniak, J., Simigdala, N., Thornhill, A., Avogadri-Connors, F., Cutler, R., Lalani, A., Dowsett, M., Johnston, S. and Martin, L. 2018. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer. Breast Cancer Research. 20, p. 44 44. https://doi.org/10.1186/S13058-018-0983-1

TitleTargeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer
TypeJournal article
AuthorsRibas, R., Pancholi, S., Rani, A., Schuster, E., Guest, S., Nikitorowicz-Buniak, J., Simigdala, N., Thornhill, A., Avogadri-Connors, F., Cutler, R., Lalani, A., Dowsett, M., Johnston, S. and Martin, L.
Abstract

Background
Endocrine therapies are the mainstay of treatment for oestrogen receptor (ER)-positive (ER+) breast cancer (BC). However, resistance remains problematic largely due to enhanced cross-talk between ER and growth factor pathways, circumventing the need for steroid hormones. Previously, we reported the anti-proliferative effect of everolimus (RAD001-mTORC1 inhibitor) with endocrine therapy in resistance models; however, potential routes of escape from treatment via ERBB2/3 signalling were observed. We hypothesised that combined targeting of three cellular nodes (ER, ERBB, and mTORC1) may provide enhanced long-term clinical utility.

Methods
A panel of ER+ BC cell lines adapted to long-term oestrogen deprivation (LTED) and expressing ESR1wt or ESR1Y537S, modelling acquired resistance to an aromatase-inhibitor (AI), were treated in vitro with a combination of RAD001 and neratinib (pan-ERBB inhibitor) in the presence or absence of oestradiol (E2), tamoxifen (4-OHT), or fulvestrant (ICI182780). End points included proliferation, cell signalling, cell cycle, and effect on ER-mediated transactivation. An in-vivo model of AI resistance was treated with monotherapies and combinations to assess the efficacy in delaying tumour progression. RNA-seq analysis was performed to identify changes in global gene expression as a result of the indicated therapies.

Results
Here, we show RAD001 and neratinib (pan-ERBB inhibitor) caused a concentration-dependent decrease in proliferation, irrespective of the ESR1 mutation status. The combination of either agent with endocrine therapy further reduced proliferation but the maximum effect was observed with a triple combination of RAD001, neratinib, and endocrine therapy. In the absence of oestrogen, RAD001 caused a reduction in ER-mediated transcription in the majority of the cell lines, which associated with a decrease in recruitment of ER to an oestrogen-response element on the TFF1 promoter. Contrastingly, neratinib increased both ER-mediated transactivation and ER recruitment, an effect reduced by the addition of RAD001. In-vivo analysis of an LTED model showed the triple combination of RAD001, neratinib, and fulvestrant was most effective at reducing tumour volume. Gene set enrichment analysis revealed that the addition of neratinib negated the epidermal growth factor (EGF)/EGF receptor feedback loops associated with RAD001.

Conclusions
Our data support the combination of therapies targeting ERBB2/3 and mTORC1 signalling, together with fulvestrant, in patients who relapse on endocrine therapy and retain a functional ER.

Article number44
JournalBreast Cancer Research
Journal citation20, p. 44
ISSN1465-5411
Year2018
PublisherSpringer Science and Business Media LLC
BMC
Publisher's version
License
CC BY 4.0
File Access Level
Open (open metadata and files)
Digital Object Identifier (DOI)https://doi.org/10.1186/S13058-018-0983-1
Publication dates
Published08 Jun 2018

Related outputs

Prostate Cancer: The role of inflammation and chemokines
Rani, A., Dasgupta, P. and Murphy, J.J. 2019. Prostate Cancer: The role of inflammation and chemokines. American Journal of Pathology. 189 (11), pp. 2119-2137. https://doi.org/10.1016/j.ajpath.2019.07.007

Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy
Rani, A., Stebbing, J., Giamas, G. and Murphy, J.J. 2019. Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy. Frontiers in Endocrinology. 10 245. https://doi.org/10.3389/fendo.2019.00245

PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers
Coffey, G., Rani, A., Betz, A., Pak, Y., Haberstock-Debic, H., Pandey, A., Hollenbach, S., Gretler, D.D., Mant, T., Jurcevic, S. and Sinha, U. 2017. PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers. Journal of Clinical Pharmacology . 57 (2), p. 194–210. https://doi.org/10.1002/jcph.794

HES1 in immunity and cancer
Rani, A., Greenlaw, R., Smith, R.A. and Galustian, C. 2016. HES1 in immunity and cancer. Cytokine & Growth Factor Reviews. 30, pp. 113-117. https://doi.org/10.1016/j.cytogfr.2016.03.010

STAT5 in Cancer and Immunity
Murphy, J.J. and Rani, A. 2016. STAT5 in Cancer and Immunity. Journal of Interferon & Cytokine Research. 36 (4), pp. 226-237. https://doi.org/10.1089/jir.2015.0054

Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer
López-Knowles, E., Wilkerson, P., Ribas, R., Anderson, H., Mackay, A., Ghazoui, Z., Rani, A., Osin, P., Nerurkar, A., Renshaw, L., Larionov, A., Miller, W., Dixon, J., Reis-Filho, J., Dunbier, A., Martin, L. and Dowsett, M. 2015. Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer. Breast Cancer Research. 17, p. 35 35. https://doi.org/10.1186/S13058-015-0532-0

The Notch target Hes1, is a STAT5 target gene with implications in cancer
Rani, A., Greenlaw, R., Galustian, C. and Murphy, J.J. 2015. The Notch target Hes1, is a STAT5 target gene with implications in cancer. 2015 Meeting of the ICIS in Bamberg, Germany, October 11th -14th. Bamberg, Germany Oct 2015 https://doi.org/10.1016/j.cyto.2015.08.214

Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor–positive breast cancers
Ribas, R., Ghazoui, Z., Gao, Q., Pancholi, S., Rani, A., Dunbier, A., Dowsett, M. and Martin, L. 2014. Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor–positive breast cancers. Breast Cancer Research. 16, p. 447 447. https://doi.org/10.1186/s13058-014-0447-1

IL-2 Regulates Expression of C-MAF in Human CD4 T Cells
Rani, A., Afzali, B., Kelly, A., Tewolde-Berhan, L., Hacket, M., Kanhere, A., Pedroza-Pacheco, I., Bowen, H., Jurcevic, S., Jenner, R., Cousins, D., Ragheb, J., Lavender, P. and John, S. 2011. IL-2 Regulates Expression of C-MAF in Human CD4 T Cells. Journal of Immunology. 187 (7), pp. 3721-3729. https://doi.org/10.4049/jimmunol.1002354

Permalink - https://westminsterresearch.westminster.ac.uk/item/qz6x1/targeting-tumour-re-wiring-by-triple-blockade-of-mtorc1-epidermal-growth-factor-and-oestrogen-receptor-signalling-pathways-in-endocrine-resistant-breast-cancer


Share this
Tweet
Email

Usage statistics

7 total views
10 total downloads
0 views this month
1 downloads this month
These values are for the period from September 2nd 2018, when this repository was created

Export as